ETAR antagonist ZD4054 exhibits additive effects with aromatase inhibitors and fulvestrant in breast cancer therapy, and improves in vivo efficacy of anastrozole
Martin Smollich, Martin Götte, Jeanett Fischgräbe, Luciana F. MacEdo, Angela Brodie, Shiuan Chen, Isabel Radke, Ludwig Kiesel, Pia Wülfing*
Untersuchen Sie die Forschungsthemen von „ETAR antagonist ZD4054 exhibits additive effects with aromatase inhibitors and fulvestrant in breast cancer therapy, and improves in vivo efficacy of anastrozole“. Zusammen bilden sie einen einzigartigen Fingerprint.